Arena's Lorcaserin Reaches FDA, But Without REMS Proposal

Arena Pharmaceuticals filed the NDA for its obesity drug lorcaserin Dec. 22, crossing the top item off the firm's news flow list and refocusing attention on the drug's partnering potential in a shifting regulatory and competitive landscape